U.S. pharmaceutical powerhouse Eli Lilly and Company and South Korea’s Hanmi Pharm have formalized a definitive licensing and commercialization agreement valued at up to $1.26 billion. The transaction centers on the development of Hanmi’s novel biologic drug candidate, sonefpeglutide (a LAPS GLP-2 analogue), designed to target severe intestinal and gastrointestinal conditions. The cross-border alliance underscores Eli Lilly’s aggressive dealmaking momentum throughout 2026, which featured its recent acquisition of three vaccine-specialist biotech firms last month to scale its core infectious disease portfolio.
The financial breakdowns, tiered structural layout, and localized clinical parameters tracking the biologic candidate include:
-
Territorial Rights and Operational Milestones: Under the terms of the contract, Eli Lilly secures exclusive worldwide rights to develop, manufacture, and commercialize sonefpeglutide outside of South Korea. In terms of clinical execution, Hanmi Pharm retains operational responsibility to steer the ongoing global Phase II registration trial for short bowel syndrome (SBS) through to completion. Concurrently, Eli Lilly will spearhead subsequent clinical development vectors, leveraging available clinical and non-clinical data sets.
-
Upfront Allocation and Milestone Frameworks: In exchange for the international commercial rights, Hanmi Pharm will receive an immediate upfront cash consideration of $75 million. The South Korean developer remains eligible to secure up to an additional $1.185 billion in conditional payments tied to predefined clinical development timelines, global regulatory approvals, and final commercialization metrics, supplemented by tiered royalties following the product’s official launch.
-
Proprietary Long-Acting Biologics Platform: Sonefpeglutide is engineered using Hanmi’s proprietary LAPSCOVERY long-acting platform technology. The underlying biological infrastructure has demonstrated commercial and clinical validity, having previously underpinned another biologic candidate that successfully captured marketing approval from the U.S. Food and Drug Administration (FDA). Hanmi Pharm is currently advancing five alternative global clinical programs leveraging this identical tech platform.
-
Biological Mechanism of Action: Non-clinical evaluation of LAPS GLP-2 confirmed its functional capacity to optimize intestinal tissue growth, mitigate chronic gastrointestinal inflammation, and drive the systematic regeneration of the intestinal mucosa. These combined therapeutic properties position the molecule to effectively treat a wide array of gastrointestinal conditions beyond short bowel syndrome.
Hanmi Vice-Chairman Juhyun Lim noted that it is highly meaningful that Lilly, recognized globally as a closely watched innovator, has highly acknowledged the structural development potential defining sonefpeglutide. The agreement aligns cleanly with Hanmi Pharm’s broader corporate pipeline strategy to secure international partnerships and scale platform-based R&D targeting oncology, rare diseases, obesity, and metabolic syndromes.
Source: https://finance.yahoo.com/sectors/healthcare/articles/lilly-hanmi-sign-1-26bn-101641555.html